Aquestive Therapeutics, Inc.
AQST
$6.46
$0.315.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -96.00% | -152.89% | -88.55% | -460.83% | -190.59% |
| Total Depreciation and Amortization | -44.79% | -48.03% | -46.33% | -45.99% | -26.14% |
| Total Amortization of Deferred Charges | 11.54% | 50.99% | 135.15% | 443.31% | 4,129.74% |
| Total Other Non-Cash Items | 34.40% | 33.56% | 37.61% | 97.30% | 231.31% |
| Change in Net Operating Assets | 89.80% | 72.03% | -68.16% | -86.43% | -205.63% |
| Cash from Operations | -47.47% | -101.32% | -90.68% | -460.49% | -590.28% |
| Capital Expenditure | -207.50% | -45.89% | 74.07% | 84.02% | 84.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -207.50% | -45.89% | 74.07% | 84.02% | 84.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 99.93% | 99.93% | 99.94% | 99.96% | -210.80% |
| Issuance of Common Stock | 16.84% | -76.63% | -76.32% | 390.88% | 505.70% |
| Repurchase of Common Stock | 21.82% | -10.47% | -1.67% | -9,909.09% | -9,900.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.20% | -100.20% | -100.12% | -100.07% | 578.14% |
| Cash from Financing | 16.90% | -77.60% | -76.30% | 2,003.47% | 29,509.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.41% | -143.50% | -138.85% | 1,501.76% | 745.18% |